S&P 500   2,970.16 (0.00%)
DOW   26,845.69 (+0.11%)
QQQ   191.35 (+0.13%)
AAPL   237.21 (+0.42%)
FB   184.06 (-0.07%)
MSFT   139.90 (+0.16%)
AMZN   1,727.63 (-0.25%)
CGC   18.94 (-2.52%)
BABA   171.60 (-0.77%)
GE   8.75 (-0.57%)
TSLA   255.82 (+3.20%)
T   37.42 (-0.43%)
ACB   3.50 (-5.16%)
PRI   121.45 (-0.20%)
NFLX   283.39 (+0.16%)
DIS   129.74 (-0.22%)
S&P 500   2,970.16 (0.00%)
DOW   26,845.69 (+0.11%)
QQQ   191.35 (+0.13%)
AAPL   237.21 (+0.42%)
FB   184.06 (-0.07%)
MSFT   139.90 (+0.16%)
AMZN   1,727.63 (-0.25%)
CGC   18.94 (-2.52%)
BABA   171.60 (-0.77%)
GE   8.75 (-0.57%)
TSLA   255.82 (+3.20%)
T   37.42 (-0.43%)
ACB   3.50 (-5.16%)
PRI   121.45 (-0.20%)
NFLX   283.39 (+0.16%)
DIS   129.74 (-0.22%)
Log in

Ibio Stock Price, News & Analysis (NYSEAMERICAN:IBIO)

-0.01 (-2.22 %)
(As of 10/14/2019 11:51 AM ET)
Today's Range
Now: $0.44
50-Day Range N/A
52-Week Range
Now: $0.44
Volume47,228 shs
Average Volume356,713 shs
Market Capitalization$10.61 million
P/E RatioN/A
Dividend YieldN/A
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNASDAQ:IBIO



Sales & Book Value

Annual SalesN/A



Market Cap$10.61 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

When did Ibio's stock split? How did Ibio's stock split work?

Shares of Ibio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

When is Ibio's next earnings date?

Ibio is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Ibio.

Has Ibio been receiving favorable news coverage?

Media headlines about IBIO stock have been trending negative on Monday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ibio earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Ibio.

Are investors shorting Ibio?

Ibio saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 213,200 shares, an increase of 44.3% from the August 15th total of 147,700 shares. Based on an average daily trading volume, of 933,200 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.0% of the shares of the company are sold short. View Ibio's Current Options Chain.

Who are some of Ibio's key competitors?

What other stocks do shareholders of Ibio own?

Who are Ibio's key executives?

Ibio's management team includes the folowing people:
  • Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
  • Mr. Robert L. Erwin, Pres (Age 66)
  • Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
  • Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
  • Dr. Renato Lobo, Chief Medical Officer

How do I buy shares of Ibio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ibio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.44.

How big of a company is Ibio?

Ibio has a market capitalization of $10.61 million. Ibio employs 54 workers across the globe.View Additional Information About Ibio.

What is Ibio's official website?

The official website for Ibio is http://www.ibioinc.com/.

How can I contact Ibio?

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

MarketBeat Community Rating for Ibio (NYSEAMERICAN IBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe IBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel